4.7 Article

Deubiquitylating enzyme USP9x regulates radiosensitivity in glioblastoma cells by Mcl-1-dependent and -independent mechanisms

Journal

CELL DEATH & DISEASE
Volume 7, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/cddis.2015.405

Keywords

-

Categories

Funding

  1. 'IZKF-Promotionskolleg' of the University Hospital Tuebingen
  2. Wilhelm-Sander-Stiftung [2011.083.1]
  3. DFG [GRK1739]
  4. 'Deutsche Krebshilfe' [110355]

Ask authors/readers for more resources

Glioblastoma is a very aggressive form of brain tumor with limited therapeutic options. Usually, glioblastoma is treated with ionizing radiation (IR) and chemotherapy after surgical removal. However, radiotherapy is frequently unsuccessful, among others owing to resistance mechanisms the tumor cells have developed. Antiapoptotic B-cell leukemia (Bcl)-2 family members can contribute to radioresistance by interfering with apoptosis induction in response to IR. Bcl-2 and the closely related Bcl-xL and Mcl-1 are often overexpressed in glioblastoma cells. In contrast to Bcl-2 and Bcl-xL, Mcl-1 is a short-lived protein whose stability is closely regulated by ubiquitylation-dependent proteasomal degradation. Although ubiquitin ligases facilitate degradation, the deubiquitylating enzyme ubiquitin-specific protease 9x (USP9x) interferes with degradation by removing polyubiquitin chains from Mcl-1, thereby stabilizing this protein. Thus, an inability to downregulate Mcl-1 by enhanced USP9x activity might contribute to radioresistance. Here we analyzed the impact of USP9x on Mcl-1 levels and radiosensitivity in glioblastoma cells. Correlating Mcl-1 and USP9x expressions were significantly higher in human glioblastoma than in astrocytoma. Downregulation of Mcl-1 correlated with apoptosis induction in established glioblastoma cell lines. Although Mcl-1 knockdown by siRNA increased apoptosis induction after irradiation in all glioblastoma cell lines, USP9x knockdown significantly improved radiation-induced apoptosis in one of four cell lines and slightly increased apoptosis in another cell line. In the latter two cell lines, USP9x knockdown also increased radiation-induced clonogenic death. The massive downregulation of Mcl-1 and apoptosis induction in A172 cells transfected with USP9x siRNA shows that the deubiquitinase regulates cell survival by regulating Mcl-1 levels. In contrast, USP9x regulated radiosensitivity in Ln229 cells without affecting Mcl-1 levels. We conclude that USP9x can control survival and radiosensitivity in glioblastoma cells by Mcl-1-dependent and Mcl-1-independent mechanisms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models

Corinna J. Mohr, Werner Schroth, Thomas E. Muerdter, Dominic Gross, Selina Maier, Benjamin Stegen, Alice Dragoi, Friederike A. Steudel, Severine Stehling, Reiner Hoppe, Stephen Madden, Peter Ruth, Stephan M. Huber, Hiltrud Brauch, Robert Lukowski

Summary: Pore-forming alpha subunits of the BK channel play a role in promoting breast cancer, while the absence or knockdown of BK subunits attenuate the proliferation of breast cancer cells. Tamoxifen stimulates the proliferation of breast cancer cells at low concentrations.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Article Cell & Tissue Engineering

The vascular nature of lung-resident mesenchymal stem cells

Jennifer Steens, Lea Klar, Christine Hansel, Alexis Slama, Thomas Hager, Verena Jendrossek, Clemens Aigner, Diana Klein

Summary: Human lungs contain endogenous mesenchymal stem cells, with lung-resident MSCs predominantly located in the vascular stem cell niche of lung arteries. These LR-MSCs bear similarities to MSCs derived from adult human blood vessel walls, expressing a specific HOX code. The identification of LR-MSCs as VW-MSCs has implications for understanding lung physiology, pulmonary diseases, and therapeutic approaches.

STEM CELLS TRANSLATIONAL MEDICINE (2021)

Article Oncology

Stromal Fibroblasts Counteract the Caveolin-1-Dependent Radiation Response of LNCaP Prostate Carcinoma Cells

Alina Wittka, Julia Ketteler, Lars Borgards, Patrick Maier, Carsten Herskind, Verena Jendrossek, Diana Klein

Summary: In prostate cancer, inhibiting the gain of CAV1 in malignant epithelial cells and limiting the loss of stromal CAV1 are crucial for improving the response to radiotherapy. Additionally, targeting activated stromal fibroblasts by limiting fibroblast activation plays a key role in inhibiting the resistance-promoting CAV1-dependent signals of the tumor stroma.

FRONTIERS IN ONCOLOGY (2022)

Article Multidisciplinary Sciences

PHGDH heterogeneity potentiates cancer cell dissemination and metastasis

Matteo Rossi, Patricia Altea-Manzano, Margherita Demicco, Ginevra Doglioni, Laura Bornes, Marina Fukano, Anke Vandekeere, Alejandro M. Cuadros, Juan Fernandez-Garcia, Carla Riera-Domingo, Cristina Jauset, Melanie Planque, H. Furkan Alkan, David Nittner, Dongmei Zuo, Lindsay A. Broadfield, Sweta Parik, Antonino Alejandro Pane, Francesca Rizzollo, Gianmarco Rinaldi, Tao Zhang, Shao Thing Teoh, Arin B. Aurora, Panagiotis Karras, Ines Vermeire, Dorien Broekaert, Joke Van Elsen, Maximilian M. L. Knott, Martin F. Orth, Sofie Demeyer, Guy Eelen, Lacey E. Dobrolecki, Ayse Bassez, Thomas Van Brussel, Karl Sotlar, Michael T. Lewis, Harald Bartsch, Manfred Wuhrer, Peter van Veelen, Peter Carmeliet, Jan Cools, Sean J. Morrison, Jean-Christophe Marine, Diether Lambrechts, Massimiliano Mazzone, Gregory J. Hannon, Sophia Y. Lunt, Thomas G. P. Grunewald, Morag Park, Jacco van Rheenen, Sarah-Maria Fendt

Summary: The loss of phosphoglycerate dehydrogenase (PHGDH) has been found to increase cancer metastasis. Heterogeneous or low expression of PHGDH in primary tumors of breast cancer patients is associated with decreased metastasis-free survival time. Loss of PHGDH activates the hexosamine-sialic acid pathway through its interaction with the glycolytic enzyme phosphofructokinase, leading to increased cell migration and invasion.

NATURE (2022)

Correction Cell Biology

Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy (vol 12, 694, 2021)

Violetta Ritter, Franziska Krautter, Diana Klein, Verena Jendrossek, Justine Rudner

CELL DEATH & DISEASE (2022)

Article Cell Biology

Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells

Luca Hegedues, Kata D. Szuecs, Matthias Kudla, Julian Heidenreich, Verena Jendrossek, Samuel Pena-Llopis, Tamas Garay, Andras Czirok, Clemens Aigner, Till Ploenes, Silvia Vega-Rubin-de-Celis, Balazs Hegedues

Summary: This study investigated the effect of Nintedanib on SRC kinase, one of its targets, in MPM cells. The results showed that Nintedanib did not inhibit SRC activation and even increased SRC phosphorylation in some MPM cell lines. However, combination treatment with the SRC inhibitor Dasatinib reversed this effect. The study also revealed that combination treatment promoted autophagy in MPM cells, which was independent of the AKT/mTOR and ERK pathways.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Article Cell Biology

Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: A metabolic strategy for induction of HR-ness and radiosensitivity

Kexu Xiang, Christian Kalthoff, Corinna Muench, Verena Jendrossek, Johann Matschke

Summary: Inhibition of SLC25A1 leads to accumulation of oncometabolite D-2-HG, increasing the sensitivity of cancer cells to radiotherapy and delaying DNA damage repair. Combining SLC25A1 inhibition with PARP or DNA-PKcs inhibitors further enhances radiotherapy-induced DNA damage and delays repair, resulting in increased radiosensitivity of cancer cells.

CELL DEATH & DISEASE (2022)

Article Oncology

Targeting AKT-Dependent Regulation of Antioxidant Defense Sensitizes AKT-E17K Expressing Cancer Cells to Ionizing Radiation

Isabell Goetting, Safa Larafa, Katharina Eul, Mikhail Kunin, Burkhard Jakob, Johann Matschke, Verena Jendrossek

Summary: Aberrant activation of AKT affects cellular antioxidant defense and radiosensitivity. TRAMPC1 cells overexpressing the clinically relevant AKT variant AKT-E17K exhibit improved antioxidant defense and increased radiation resistance. This change is associated with AKT-dependent regulation of cellular levels of reduced glutathione (GSH), both directly and indirectly. Pharmacological inhibition of AKT-dependent metabolic enzymes supporting defense against oxidative stress, such as glutathione synthase and glutathione reductase, enhances the eradication of clonogenic tumor cells, particularly those overexpressing AKT-E17K.

FRONTIERS IN ONCOLOGY (2022)

Correction Multidisciplinary Sciences

PHGDH heterogeneity potentiates cancer cell dissemination and metastasis (vol 605. pg 747, 2022)

Matteo Rossi, Patricia Altea-Manzano, Margherita Demicco, Ginevra Doglioni, Laura Bornes, Marina Fukano, Anke Vandekeere, Alejandro M. Cuadros, Juan Fernandez-Garcia, Carla Riera-Domingo, Cristina Jauset, Melanie Planque, H. Furkan Alkan, David Nittner, Dongmei Zuo, Lindsay A. Broadfield, Sweta Parik, Antonino Alejandro Pane, Francesca Rizzollo, Gianmarco Rinaldi, Tao Zhang, Shao Thing Teoh, Arin B. Aurora, Panagiotis Karras, Ines Vermeire, Dorien Broekaert, Joke Van Elsen, Maximilian M. L. Knott, Martin F. Orth, Sofie Demeyer, Guy Eelen, Lacey E. Dobrolecki, Ayse Bassez, Thomas Van Brussel, Karl Sotlar, Michael T. Lewis, Harald Bartsch, Manfred Wuhrer, Peter van Veelen, Peter Carmeliet, Jan Cools, Sean J. Morrison, Jean-Christophe Marine, Diether Lambrechts, Massimiliano Mazzone, Gregory J. Hannon, Sophia Y. Lunt, Thomas G. P. Grunewald, Morag Park, Jacco van Rheenen, Sarah-Maria Fendt

NATURE (2022)

Article Oncology

CD9-and CD81-positive extracellular vesicles provide a marker to monitor glioblastoma cell response to photon-based and proton-based radiotherapy

Sara Jennrich, Martin Pelzer, Tobias Tertel, Benjamin Koska, Melanie Vullings, Basant Kumar Thakur, Verena Jendrossek, Beate Timmermann, Bernd Giebel, Justine Rudner

Summary: Glioblastoma multiforme (GBM) is an aggressive tumor of the central nervous system with limited treatment options. Radiation therapy, specifically proton-based irradiation, shows promising results in treating GBM tumors. Extracellular vesicles (EVs) released by GBM cells can potentially serve as markers for predicting tumor response to radiotherapy.

FRONTIERS IN ONCOLOGY (2022)

Article Multidisciplinary Sciences

CD47 restricts antiviral function of alveolar macrophages during influenza virus infection

Christina Wenzek, Philine Steinbach, Florian Wirsdoerfer, Kathrin Sutter, Julia D. Boehme, Robert Geffers, Robert Klopfleisch, Dunja Bruder, Verena Jendrossek, Jan Buer, Astrid M. Westendorf, Torben Knuschke

Summary: CD47 plays a significant role in immune responses, but its role in antiviral immunity is not fully understood. This study revealed that CD47-deficient mice showed enhanced clearance of IAV, and this enhanced clearance was mediated by aM Phi. The study also found that CD47 restricts HB expression in aM Phi after IAV and SARS-CoV-2 infection, and HB enhances the IFN-b response, showing antiviral properties.

ISCIENCE (2022)

Article Cell Biology

A Lamb1Dendra2 mouse model identifies basement-membrane-producing origins and dynamics in PyMT breast tumors

Jessica Morgner, Laura Bornes, Kerstin Hahn, Carmen Lopez-Iglesias, Lona Kroese, Colin E. J. Pritchard, Claire Vennin, Peter J. Peters, Ivo Huijbers, Jacco van Rheenen

Summary: This study reveals that the basement membrane (BM) surrounding mammary tumors has a faster turnover rate of laminin beta1 compared to the BM surrounding healthy epithelium. Cancer cells and tumor-infiltrating endothelial cells are found to synthesize laminin beta1, but its production is heterogeneous and temporary, leading to local discontinuity and even disappearance of the BM.

DEVELOPMENTAL CELL (2023)

Article Oncology

Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis-The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging

Nika Guberina, Florian Wirsdoerfer, Martin Stuschke, Verena Jendrossek

Summary: The risk of overlapping pulmonary toxicity induced by thoracic radio(chemo)therapy and immune checkpoint inhibitor therapy in the treatment of patients suffering from non-small cell lung cancer (NSCLC) is a significant challenge in successful radioimmunotherapy. Factors such as patient selection, monitoring biomarkers, and early detection of lung tissue changes play crucial roles in optimizing treatment outcomes and minimizing side effects. The concurrent use of radiotherapy and immunotherapy can provide new curative options for locally advanced NSCLC patients, but careful management of adverse events, especially in the lung, is necessary.

NEOPLASIA (2023)

Article Immunology

Comparative transcriptomic and proteomic signature of lung alveolar macrophages reveals the integrin CD11b as a regulatory hub during pneumococcal pneumonia infection

Kristina Zec, Stephanie Thiebes, Jenny Bottek, Devon Siemes, Philippa Spangenberg, Duc Viet Trieu, Nils Kirstein, Nirojah Subramaniam, Robin Christ, Diana Klein, Verena Jendrossek, Maria Loose, Florian Wagenlehner, Jadwiga Jablonska, Thilo Bracht, Barbara Sitek, Bettina Budeus, Ludger Klein-Hitpass, Dirk Theegarten, Olga Shevchuk, Daniel R. Engel

Summary: This study provides novel insights into the molecular adaptations of alveolar macrophages (AM) upon lung infection with Streptococcus pneumoniae. The results reveal a strong neutrophil-associated proteomic signature in AM, and identify CD11b as a central molecular hub influencing neutrophil recruitment, activation, and migration.

FRONTIERS IN IMMUNOLOGY (2023)

Meeting Abstract Immunology

CD47 restricts antiviral function of alveolar macrophages during influenza A virus infection

C. Wenzek, P. Steinbach, F. Wirsdoerfer, K. Sutter, J. D. Boehme, R. Geffers, D. Bruder, V. Jendrossek, J. Buer, A. M. Westendorf, T. Knuschke

EUROPEAN JOURNAL OF IMMUNOLOGY (2022)

No Data Available